499 related articles for article (PubMed ID: 9430472)
1. D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.
Bernard BF; Krenning EP; Breeman WA; Rolleman EJ; Bakker WH; Visser TJ; Mäcke H; de Jong M
J Nucl Med; 1997 Dec; 38(12):1929-33. PubMed ID: 9430472
[TBL] [Abstract][Full Text] [Related]
2. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.
de Jong M; Bakker WH; Krenning EP; Breeman WA; van der Pluijm ME; Bernard BF; Visser TJ; Jermann E; Béhé M; Powell P; Mäcke HR
Eur J Nucl Med; 1997 Apr; 24(4):368-71. PubMed ID: 9096086
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo.
de Jong M; Rolleman EJ; Bernard BF; Visser TJ; Bakker WH; Breeman WA; Krenning EP
J Nucl Med; 1996 Aug; 37(8):1388-92. PubMed ID: 8708781
[TBL] [Abstract][Full Text] [Related]
5. A comparison of biodistribution between 111In-DTPA octreotide and 111In-DOTATOC in rats bearing pancreatic tumors.
Lin YC; Hung GU; Luo TY; Chen CH; Hsia CC; Hen SL; Ho YJ; Lin WY
J Vet Med Sci; 2006 Apr; 68(4):367-71. PubMed ID: 16679728
[TBL] [Abstract][Full Text] [Related]
6. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
7. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.
Rolleman EJ; Valkema R; de Jong M; Kooij PP; Krenning EP
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):9-15. PubMed ID: 12483404
[TBL] [Abstract][Full Text] [Related]
8. Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.
van Eerd JE; Vegt E; Wetzels JF; Russel FG; Masereeuw R; Corstens FH; Oyen WJ; Boerman OC
J Nucl Med; 2006 Mar; 47(3):528-33. PubMed ID: 16513623
[TBL] [Abstract][Full Text] [Related]
9. Oral versus intravenous administration of lysine: equal effectiveness in reduction of renal uptake of [111In-DTPA]octreotide.
Verwijnen SM; Krenning EP; Valkema R; Huijmans JG; de Jong M
J Nucl Med; 2005 Dec; 46(12):2057-60. PubMed ID: 16330570
[TBL] [Abstract][Full Text] [Related]
10. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
[TBL] [Abstract][Full Text] [Related]
11. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
[TBL] [Abstract][Full Text] [Related]
12. Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose.
Rolleman EJ; Krenning EP; Van Gameren A; Bernard BF; De Jong M
J Nucl Med; 2004 Apr; 45(4):709-13. PubMed ID: 15073269
[TBL] [Abstract][Full Text] [Related]
13. Distribution and elimination characteristics of 111In-DTPA-D-phe1-octreotide and 111In-DTPA-L-phe1-octreotide in rats.
Laznickova A; Laznicek M; Trejtnar F; Melicharova L; Suzuki KH; Akizawa H; Arano Y; Yokoyama A
Eur J Drug Metab Pharmacokinet; 2002; 27(1):37-43. PubMed ID: 11996325
[TBL] [Abstract][Full Text] [Related]
14. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
[TBL] [Abstract][Full Text] [Related]
15. Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.
Helisch A; Förster GJ; Reber H; Buchholz HG; Arnold R; Göke B; Weber MM; Wiedenmann B; Pauwels S; Haus U; Bouterfa H; Bartenstein P
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1386-92. PubMed ID: 15175836
[TBL] [Abstract][Full Text] [Related]
16. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
17. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.
Krenning EP; de Jong M; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; Jamar F; Pauwels S; Valkema R
Ann Oncol; 1999; 10 Suppl 2():S23-9. PubMed ID: 10399029
[TBL] [Abstract][Full Text] [Related]
18. Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.
De Jong M; Breeman WA; Bernard HF; Kooij PP; Slooter GD; Van Eijck CH; Kwekkeboom DJ; Valkema R; Mäcke HR; Krenning EP
Q J Nucl Med; 1999 Dec; 43(4):356-66. PubMed ID: 10731786
[TBL] [Abstract][Full Text] [Related]
19. Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo.
Akizawa H; Arano Y; Uezono T; Ono M; Fujioka Y; Uehara T; Yokoyama A; Akaji K; Kiso Y; Koizumi M; Saji H
Bioconjug Chem; 1998; 9(6):662-70. PubMed ID: 9815158
[TBL] [Abstract][Full Text] [Related]
20. Effects of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-Octreotide (SMT487[OctreoTher) treatment.
Bushnell D; Menda Y; O'Dorisio T; Madsen M; Miller S; Carlisle T; Squires S; Kahn D; Walkner W; Connolly M; O'Dorisio S; Karwal M; Ponto J; Bouterfa H
Cancer Biother Radiopharm; 2004 Feb; 19(1):35-41. PubMed ID: 15068609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
